WeTrials
Recruiting

Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma

What is this study?

This study is testing two anti-cancer medications used together, ulixertinib and palbociclib, to find the safest and most effective dose for adults with advanced cancers. Researchers want to see how well this combination works, especially for people with certain types of pancreatic cancer and melanoma that have spread.

Who can participate?

You may be able to join if you are 18 or older, can still perform most of your daily activities, and have advanced pancreatic cancer or melanoma that has already been treated at least once. There are some safety rules, such as not being pregnant and avoiding certain citrus fruits like grapefruit during the study.

What will happen?

Participants will take the study medications and be closely monitored by the medical team to check their health, track how their body handles the treatment, and find the right dose. Your team will guide you through every step and schedule regular check-ups to see how you are doing.

Where and when?

The study is currently active and recruiting participants in Chapel Hill, North Carolina, United States.

Key Points
  • 1Tests a combination of two targeted cancer medications to find the safest dose.
  • 2Open to adults with advanced solid tumors, including specific types of pancreatic cancer and melanoma.
  • 3Currently recruiting patients in Chapel Hill, North Carolina.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Tumor, SolidPancreatic CancerMelanoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.